(AOF) – Novo Nordisk jumped 4.91% to 890.60 Danish crowns on the Copenhagen Stock Exchange after the announcements made during its investors day (CMD for Capital Markets Day). The Danish pharmaceutical laboratory already has the largest European capitalization. A new treatment called amycretin, which targets two modes of action against obesity, including GLP-1, like the group’s flagship drug, Wegovy, caused a 13% drop in patients’ weight in 12 weeks during ‘a preliminary test, Bloomberg reported.
During this event, Novo Nordisk will provide an update on the expansion of the cardiovascular disease pipeline and the expected evolution of its margin in the coming years. The Danish company will also provide an update on the increase in its production capacities as it cannot meet demand for Wegovy.
AOF – LEARN MORE
Learn more about the Pharmacy sector
Oncology, priority of pharmaceutical giants
Sanofi’s stock market disappointment recorded at the end of October 2023 underlines the new direction for the group, which has now set oncology as its number 1 priority. Efforts in this segment, where therapies are advancing the fastest, notably involve investments in R&D which weigh on profitability. Sanofi therefore announced a drop in its earnings per share in 2024 and the abandonment of its objective of an operating margin of 32% in 2025. Merck has just unveiled a new alliance. It will pay up to $22 billion to the Japanese group Daiichi Sankyo as part of a partnership on experimental cancer treatments. While some experts estimate that the United States represents nearly half of global oncology spending (drugs and treatments), or $196 billion in 2022, Chinese spending in this area has more than doubled in five years, going from 5 to 11.8 billion dollars.